How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

240 results for

Drug-induced Photosensitivity

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

102. Systemic lupus erythematosus

a flare of systemic disease. Sometimes a more generalised form over the body is present. DLE are characterised by slightly raised, scaly lesions that have a potential to scar. They can be found commonly on the scalp and face, and less commonly over the limbs and trunk. Only 5% of people with DLE have SLE, but conversely among individuals with SLE, 20% will have DLE. 17 Subacute cutaneous lupus erythematosus is another lupus-specific rash. It is a common skin manifestation in drug-induced lupus (...) , NO. 10 OCTOBER 2013 697 Cutaneous manifestations The spectrum of cutaneous manifestations of lupus erythematosus (LE) is broad, but the most classical forms associated with systemic LE are the acute malar and chronic discoid lupus erythematosus (DLE) rash. Both can be quite photosensitive in nature. 15,16 Acute malar rash is a slightly raised erythematous rash of the face, particularly cheeks and nose, with nasolabial sparing, known as the ‘butterfly’ rash. A worsening of the rash usually accompanies

2014 Clinical Practice Guidelines Portal

104. Cutaneous Lupus Erythematosus (CLE), Diagnosis and Monitoring

(for further information on drugs inducing CLE, please see Table 1 in the “S2k Guideline for Treatment of Cutaneous Lupus Erythematosus” [3]). SCLE is associated with SLE in 10-15% of SCLE patients [18]. Chronic cutaneous lupus erythematosus (CCLE) CCLE includes three different forms of disease: discoid LE (DLE), LE profundus/panniculitis (LEP), and chilblain LE (CHLE). Discoid lupus erythematosus (DLE) DLE is the most common form of CCLE. The lesions of this subtype are sharply bordered and present (...) be performed even in CLE patients. Usually, the ANA titer in CLE patients are low (= 1:320), varying in frequency and depending on the particular subtype (Table 6) [5, 39]. Anti-Ro/SS-A and – in less 18 cases – anti-La/SSB antibodies are characteristic for SCLE. Anti-histone antibodies are usually found in drug-induced LE, but they may also occur in conjunction with anti-dsDNA antibodies in idiopathic SLE (24–95%) [56]. Autoantibodies against ds- DNA and Sm are in the majority of cases associated with SLE

2013 European Dermatology Forum

106. Photodynamic therapy combined to cisplatin potentiates cell death responses of cervical cancer cells. Full Text available with Trip Pro

accessed via flow cytometry with anti-gama-H2AX and micronuclei assay, respectively. Data were analyzed by one-way ANOVA with Tukey's posthoc test.Both MBPDT and PGPDT induced caspase-independent death, but MBPDT induced the morphology of typical necrosis, while PGPDT induced morphological alterations most similar to apoptosis. Cisplatin predominantly induced apoptosis, and the combined therapy induced variable rates of apoptosis- or necrosis-like phenotypes according to the cell line (...) Photodynamic therapy combined to cisplatin potentiates cell death responses of cervical cancer cells. Photodynamic therapy (PDT) has proven to be a promising alternative to current cancer treatments, especially if combined with conventional approaches. The technique is based on the administration of a non-toxic photosensitizing agent to the patient with subsequent localized exposure to a light source of a specific wavelength, resulting in a cytotoxic response to oxidative damage. The present

2017 BMC Cancer

107. Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

absolute or relative contraindication to phototherapy, including photosensitizing disorders. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause. Known HIV positive status. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information (...) a candidate for phototherapy or systemic therapy Body Surface Area (BSA) ≥ 5%. Physical exam within clinically acceptable limits. Exclusion criteria Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. Subject has predominantly non-plaque form of psoriasis. Subject has drug-induced psoriasis. Subject with current, or a history of, severe psoriatic arthritis well controlled on current therapy. Patient has

2017 Clinical Trials

108. Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress Full Text available with Trip Pro

and in vivo. There was certain anti-tumor effect and ROS production even under cooling conditions. Repeated NIR irradiation increased the cell toxicity of ICG-NIR therapy; the mean tumor volume on day 9 was significantly smaller after ICG-NIR irradiation compared to tumor without irradiation (87 mm3 vs. 1332 mm3; p = 0.01) in HCC mice xenografts model. ICG-NIR therapy induced apoptosis in HCC cells via a photothermal effect and oxidative stress. Repeated ICG-NIR irradiation enhanced the anti-tumor effect. (...) Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress Indocyanine green (ICG) is a photothermal agent, photosensitizer, and fluorescence imaging probe which shows specific accumulation in hepatocellular carcinoma (HCC) cells. We recently developed a photodynamic therapy (PDT) using ICG and near-infrared (NIR) laser as a new anti-cancer treatment for HCC. However, the molecular mechanism underlying

2017 Scientific reports

109. An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis History of photosensitivity Subject has used ustekinumab and/or anti-IL-17 biologic therapy within 24 weeks or other experimental or commercially available biologic immune modulator(s) within 12 weeks prior to the first IP dose. Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer). Use of oral systemic medications for the treatment

2017 Clinical Trials

110. Age-Related Macular Degeneration

is that straight lines appear crooked. Regular comprehensive eye exams can detect macular degeneration before the disease causes vision loss. Treatment can slow vision loss. It does not restore vision. NIH: National Eye Institute Definition (CSP) deterioration of the macula lutea in the retina; may be inherited, drug induced, or due to aging; leads to a severe loss of central vision while peripheral vision is retained. Concepts Disease or Syndrome ( T047 ) SnomedCT 422338006 , 302891003 LNC MTHU020821 English (...) (Macugen) Aflibercept (Eylea) X. Management: Slow progression of CNV-related Vision Loss Laser photocoagulation of subretinal blood vessels Photodynamic therapy Give IV photosensitive drug (wavelength specific) Expose eye to targeted wavelength to activate drug Experimental External beam Vitreoretinal microsurgery XI. Management: Visual aids Magnifiers Increased light sources in home environment XII. Prevention: General measures is key Control Decrease UV Light exposure ( ) Nutrition See s below

2018 FP Notebook

111. Brilique (ticagrelor)

.), to a limited extent and only 3 out of 18,000 treated patients presented adverse effects potentially related to photosensitivity on ticagrelor, specific non-clinical photosafety testing is not considered necessary at this point. 2.3.4. Ecotoxicity/environmental risk assessment The dossier for the environmental risk assessment of ticagrelor was completed at day 150 of the assessment. All outstanding issues have been addressed satisfactorily. A PECsurface water of 4.5 µg/L was calculated using an Fpen of 0.01

2011 European Medicines Agency - EPARs

112. Trajenta - linagliptin

is evident. Photosafety Linagliptin has a second absorption maximum at a wavelength of greater than 290 nm (U09-1738). Therefore, the phototoxic potential of linagliptin was evaluated in clinical setting. This was considered acceptable. Pseudo-allergy The most prominent finding in the toxicity studies in dogs was drug-induced hypersensitivity. This finding was classified as a pseudo-allergic reaction as it became apparent without prior sensitization. The reaction was associated with significantly (...) . Also N-acetyl-cystein conjugate (mercapturate) has been found in mice, monkeys and humans. These data indicate that linagliptin may be converted into a reactive intermediate, which can bind covalently to proteins, resulting in a hapten. Thus, an idiosyncratic reaction will be possible. As idiosyncratic reactions, the applicant has proposed the medical concepts of drug induced liver injury, acute renal failure and blood dyscrasia. Search in clinical trials did not reveal any drug induced liver

2011 European Medicines Agency - EPARs

113. Psychosis and schizophrenia

(mood) disorders associated with psychotic symptoms, including severe depression or bipolar disorder. These conditions are distinguished from schizophrenia by the predominance of affective symptoms that may at times trigger psychosis. In contrast, schizophrenia is dominated by psychotic symptoms that may at times be associated with affective symptoms. For more information, see the prodigy topics on , and . Drug-induced psychosis caused by cannabis, corticosteroids, opioids, cocaine, or amphetamines

2016 NICE Clinical Knowledge Summaries

114. Quantitative Multi-Parametric Magnetic Resonance Imaging of Tumor Response to Photodynamic Therapy. Full Text available with Trip Pro

standard Tofts-Kermode tracer kinetic modeling. At the end of the experiment, tumor viability was characterized by histology using NADH-diaphorase staining.The therapy induced extensive cell death in the tumor and resulted in significant reduction in tumor growth, as compared to untreated controls. Tumor T1 and T2 relaxation times remained unchanged up to 24 h, but decreased at 72 h after treatment. Tumor ADC values significantly increased at 24 h and 72 h. DCE-MRI derived tracer kinetic parameters (...) of the photosensitizer Bremachlorin, followed by 10 min laser illumination (200 mW/cm2) of the tumor 6 h post injection. MRI at 7 T was performed at baseline, directly after PDT, as well as at 24 h, and 72 h. Tumor relaxation time constants (T1 and T2) and apparent diffusion coefficient (ADC) were quantified at each time point. Additionally, Gd-DOTA dynamic contrast-enhanced (DCE) MRI was performed to estimate transfer constants (Ktrans) and volume fractions of the extravascular extracellular space (ve) using

2016 PLoS ONE

115. Possia - ticagrelor

to approximately 340 nm. However, considering that in the non-clinical pharmacokinetic studies ticagrelor was shown to reach the skin following systemic administration (p.o.), to a limited extent and only 3 out of 18,000 treated patients presented adverse effects potentially related to photosensitivity on ticagrelor, specific non-clinical photosafety testing is not considered necessary at this point. 2.3.4. Ecotoxicity/environmental risk assessment The dossier for the environmental risk assessment

2010 European Medicines Agency - EPARs

116. Diclofenac-Induced Photo-Onycholysis Full Text available with Trip Pro

Diclofenac-Induced Photo-Onycholysis Onycholysis is the detachment of the nail plate from the nail bed. If drug-induced, it can be an isolated phenomenon, but it may also accompany or follow a cutaneous phototoxicity reaction due to drug intake and exposure to ultraviolet irradiation. Photo-onycholysis is a rare photosensitivity reaction due to exposure to either a natural or artificial source of light. Many drugs are responsible for this phototoxic reaction, especially tetracyclines, psoralens

2016 Oman medical journal

117. Ketoprofen-induced photoallergic dermatitis Full Text available with Trip Pro

Ketoprofen-induced photoallergic dermatitis Drug-induced photosensitivity reactions are significant adverse effects. Ketoprofen is one of the most common drugs that can cause skin rash in sun-exposed areas. Non-steroidal anti-inflammatory drugs (NSAIDs), such as ketoprofen, are often used for a variety of symptoms, including pain and fever. An understanding of the presentation and clinical course of ketoprofen-induced photosensitivity is necessary to correctly diagnose and manage this condition (...) , are used commonly for a variety of illnesses, drug-induced photoallergic dermatitis should be high on the differential in individuals using these medications who present with acute onset of a rash in sun-exposed areas.

2016 The Indian journal of medical research

118. CdSe/ZnS quantum dots induce photodynamic effects and cytotoxicity in pancreatic cancer cells Full Text available with Trip Pro

compared with no illumination. Real-time PCR showed that expression of Bax and caspase-3 was upregulated and Bcl-2 was downregulated. Immunoblotting results were consistent with real-time PCR results. Inhibition of ROS and apoptosis both attenuated QD-photodynamic-therapy-induced cell death.CdSe/ZnS QDs can be used as a photosensitizer to inhibit SW1990 cell proliferation through ROS generation and apoptotic protein expression regulation.

2016 World Journal of Gastroenterology

119. Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

by the Mini-Mental State Examination (MMSE) score of ≤ 26 Presence of depression defined as the Beck Depression Inventory (BDI) score >14 Untreated hallucinations or psychosis (drug-induced or spontaneous) Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to taper these drugs and will become eligible 4 weeks after the taper is completed Use of Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) antidepressants, unless (...) the participant has been on a stable dose for at least 3 months prior to the screening Use of medications known to affect melatonin secretion, such as lithium, alpha- and beta-adrenergic antagonists Shift work, currently or within the prior 3 months Travel through ≥ 2 time zones within 60 days prior to study screening Hematocrit <32 mm3 Pre-existing glaucoma/retinal disease contraindicated for light therapy (LT) Dense cataracts Use of medications known to photosensitize retinal tissue (phenothiazines

2016 Clinical Trials

120. Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

cases of psoriasis arthritis are allowed provided there is no impact on study objectives as determined by the Investigator. Patients with drug-induced psoriasis. Evidence of skin conditions at the time of screening visit other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis. Patients with any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form. Pregnant (...) been excised according to guidelines within the last 5 years or in situ cervical carcinoma that has been fully treated and shows no evidence of recurrence are allowed. Clinically significant abnormality on 12-lead electrocardiogram (ECG) at screening. Positive human immunodeficiency virus (HIV), hepatitis B or hepatitis C laboratory result. Previous strong sun exposure (eg, sea holiday) within the 28 days before study medication initiation. Known photo allergy and/or experienced drug-induced photo

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>